Genentech has developed a unique one-armed antibody, onartuzumab, which is now in late-stage clinical trials in multiple cancer types. The company used crystal structures obtained at ALS Beamline 5.0.2 to demonstrate the mechanism of action of this unique potentially therapeutic antibody. Read more »